Ketotifen

Ketotifen
Systematic (IUPAC) name
4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
Clinical data
Trade names Zaditor[1]
AHFS/Drugs.com Micromedex Detailed Consumer Information
MedlinePlus a604033
Pregnancy
category
  • US: C (Risk not ruled out)
Legal status
  • US: Oral — ℞-only; Eye drops — over-the counter
Routes of
administration
Oral (tablets), ophthalmic solution
Pharmacokinetic data
Bioavailability 60%
Protein binding 75%
Metabolism Hepatic
Biological half-life 12 hours
Identifiers
CAS Number 34580-14-8 YesY
ATC code R06AX17 S01GX08
PubChem CID 3827
IUPHAR/BPS 7206
DrugBank DB00920 YesY
ChemSpider 3695 YesY
UNII HBD503WORO YesY
KEGG D01332 YesY
ChEMBL CHEMBL534 YesY
Chemical data
Formula C19H19NOS
Molar mass 309.426 g/mol
  (verify)

Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis,[2] or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.

Uses

Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[3] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.

The drug may also help relieve the symptoms of irritable bowel syndrome.[4]

Side effects

Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.

Brands

Ketotifen is marketed under many brand names worldwide.[5]

See also

References

  1. http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details
  2. 1 2 Zaditor prescribing information Novartis
  3. Grahnén A; Lönnebo A; Beck O; Eckernäs SA; Dahlström B; Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharm Drug Dispos 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111.
  4. Klooker, TK; Braak, B; Koopman, KE; Welting, O; Wouters, MM; Van Der Heide, S; Schemann, M; Bischoff, SC; et al. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
  5. drugs.com International availability of ketofin Page accessed April 21, 2015

External links

This article is issued from Wikipedia - version of the Wednesday, January 13, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.